argenx misses endpoints in thrombocytopenia trial

 

• Study did not meet primary or secondary endpoints
  
  
• Favorable safety and tolerability profile consistent with previous clinical trials
  
  
• Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET)

argenx will host a conference call today at 2:30 pm CET (8:30am ET) to discuss the ADVANCE-SC results. A webcast of the live call and replay may be accessed on the Investors section of the argenx website.

Dial-in numbers:
Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                 1 888 415 4250
Japan                        81 3 4578 9081
Switzerland                41 43 210 11 32

https://www.globenewswire.com/news-release/2023/11/28/2786600/0/en/argenx-Reports-Topline-Results-from-ADVANCE-SC-Study-of-VYVGART-Hytrulo-in-Primary-Immune-Thrombocytopenia.html